ADMA Biologics is trading 7.5% up at $10.80, primarily on biotech-sector strength following positive Phase 3 personalized cancer-vaccine results from Moderna and Merck.

  • It gained 5.35% on August 19.
  • No fresh company-specific announcement was identified for August 20; the latest earnings release was August 5 and reiterated 2026 guidance.